GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

Authors

Institutions

Publication Details

Journal
International Journal of Gynecological Cancer
Published
2024-10-07
DOI
https://doi.org/10.1136/ijgc-2024-005919
Citations
22
Primary Topic
Ovarian cancer diagnosis and treatment
Type
article
Field-Weighted Citation Impact
11.82

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

Stephanie Lustgarten, Robert Louis Coleman, Bradley J. Monk, David M. Gershenson et al.
22 citations
International Journal of Gynecological Cancer
Ovarian cancer diagnosis and treatment
11.82
article

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

Stephanie Lustgarten, Robert Louis Coleman, Bradley J. Monk, David M. Gershenson, David M. O’Malley, Premal H. Thaker, Lauren Cobb, Rachel N. Grisham, Carol Aghajanian, Susana Banerjee, Hagop Youssoufian, Ana Oaknin, Kathleen N. Moore, Yeh Chen Lee, Philipp Harter, Mansoor Raza Mirza, Els Van Nieuwenhuysen, Michel Fabbro, Nicoletta Colombo, Chel Hun Choi, Amit M Oza
article en
22 citations

Abstract

No abstract available for this paper.
International Journal of Gynecological CancerVol. 35(11)
Royal Marsden NHS Foundation Trust (GB), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), University of Milan (IT), Washington University in St. Louis (US), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), Samsung Medical Center (KR), Copenhagen University Hospital (DK), Princess Margaret Cancer Centre (CA), Rigshospitalet (DK), UNSW Sydney (AU), Florida Cancer Specialists & Research Institute (US), Institut de Recherche en Cancérologie de Montpellier (FR), Kliniken Essen-Mitte (DE), The US Oncology Network (US), Verastem (United States) (US), Institut Regional du Cancer de Montpellier (FR), Vall d'Hebron Institute of Oncology (ES), European Institute of Oncology (IT), University of Oklahoma (US), KU Leuven (BE)
Verastem Oncology
Reduced inequalities
Openalex Percentile: Top 1%
Ovarian cancer diagnosis and treatment
11.82
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.